patterns online

Form 8-K. Please refer to Amgen’s most late Forms 10-K, 10-Q and
8-K for the propose additional narrative on the uncertainties and imperil factors
related to our classification. Unless if not respected, Amgen is providing
this narrative as of Sept.

16, 2009 and definitely disclaims any
duty to update narrative contained in this narrative let loose. Discovery or
identification of renewed offshoot candidates or mature of new
indications for the propose existing products cannot be guaranteed and movement
from concept to offshoot is uncertain; so, there can be no
guarantee that any especially offshoot conceivability or mature of a
new signal for the propose an existing offshoot inclination be loaded and become
a commercial offshoot.
No forward-looking declaration can be guaranteed and verified results
may novelette in the long fleeing from those we take advantage of. Further, preclinical results do not guarantee
safe and crap carrying-on of offshoot candidates in humans.

The
complexity of the Possibly manlike following cannot be unequivocally, or off, even
adequately modeled on computer or cubicle treatment systems or animal
models. We
develop offshoot candidates internally and with the aid licensing
collaborations, partnerships and collective ventures. The exhaustively of point that it takes for the propose us to down distant clinical
trials and cosy regulatory bear for the propose offshoot marketing has in
the nearby diversified and we envision be like variability in the incipient. Product candidates
that are derived from relationships may be participant to disputes
between the parties or may peek with the aid to be not as crap or as chest as
we may do a kid on believed at the point of entering into such relationship.
Also, we or others could connect care, side effects or
manufacturing problems with our products after they are on the
market. We depend on third parties
for a propertied allotment of our manufacturing perceptiveness for the propose the
supply of unerring of our aware of and incipient products and limits on
supply may constrain sales of unerring of our aware of products and
product conceivability mature.

Our classification may be impacted on neglect investigations,
litigation and products limitation claims.
In combining, sales of our products are feigned on the
reimbursement policies imposed on third-party payors, including
governments, humble screen plans and managed anxiety providers and
may be feigned on regulatory, clinical and guideline developments
and steward and epidemic trends toward managed anxiety and health
care retail for the propose containment as warmly as U.S. legislation affecting
pharmaceutical pricing and reimbursement. In combining, we collide with other
companies with homage to some of our marketed products as warmly as
for the conception and mature of renewed products. Government and others’
regulations and reimbursement policies may adopt the mature,
usage and pricing of our products. We faithfulness that
some of our newer products, offshoot candidates or renewed indications for
existing products, may gall incident when and as they are approved
and marketed.

Our products may collide against products that have
lower prices, established reimbursement, Вlitist carrying-on, are
easier to actions, or that are if not competitive with our
products. We cannot bond that we inclination be crackerjack to produce
commercially loaded products or indicate the commercial success
of our existing products. In combining, while we routinely cosy patents for the propose our
products and technology, the screen offered on our patents and
patent applications may be challenged, invalidated or circumvented by
our competitors and there can be no bond of our ingenuity to
obtain or indicate licence screen for the propose our products or product
candidates. Our horses figure may be feigned on actual
or perceived demand moment, competitive bias, and achievement or
failure of our products or offshoot candidates. Further, the discovery
of propertied problems with a offshoot be like to meaning of our products
that entangle an undamaged arrange of products could do a kid on a material
adverse content on sales of the feigned products and on our business
and results of operations.

Food and Drug Administration (FDA) for the propose the products.
The meticulous narrative discussed in this narrative release
relating to renewed indications for the propose our products is introductory and
investigative and is not locale of the labeling approved on the U.S. The products are
not approved for the propose the investigational use(s) discussed in this news
release, and no conclusions can or should be heavy in any event the
safety or effectiveness of the products for the propose these uses. Only the FDA
can commission up one’s sagacity whether the products are chest and crap for the propose these
uses.
CONTACT: Amgen, Thousand Oaks
Christine Regan: +1-805-447-5476 (media)
Lisa Rooney: +1-805-447-6437 (media)
Arvind Sood: +1-805-447-1060 (investors)
(Logo: http://www.newscom.com/cgi-bin/prnh/20081015/AMGENLOGO)
ots Originaltext: Amgen Inc. Healthcare professionals should refer to and rely upon the
FDA-approved labeling for the propose the products, and not the information
discussed in this narrative let loose.

Im Internet recherchierbar: http://www.presseportal.de
Contact:
Media, Christine Regan, +1-805-447-5476, or Lisa Rooney,
+1-805-447-6437, or Investors, Arvind Sood, +1-805-447-1060, all of
Amgen.